m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG04145)
Name
ALRN-6924
Status
Phase 2
TTD Drug ID
D07UKT
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
p53-binding protein Mdm4 (MDM4)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary p53-binding protein Mdm4 (MDM4) is a therapeutic target for ALRN-6924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ALRN-6924 through regulating the expression of p53-binding protein Mdm4 (MDM4). [1], [2]
Ubiquitin-protein ligase E3 Mdm2 (MDM2)
Methyltransferase-like 14 (METTL14)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for ALRN-6924. The Methyltransferase-like 14 (METTL14) has potential in affecting the response of ALRN-6924 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). [3], [4]
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Ubiquitin-protein ligase E3 Mdm2 (MDM2) is a therapeutic target for ALRN-6924. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of ALRN-6924 through regulating the expression of Ubiquitin-protein ligase E3 Mdm2 (MDM2). [3], [4]
References
Ref 1 Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012 Apr 29;485(7397):201-6. doi: 10.1038/nature11112.
Ref 2 Emerging therapies targeting the ubiquitin proteasome system in cancer. J Clin Invest. 2014 Jan;124(1):6-12. doi: 10.1172/JCI71602. Epub 2014 Jan 2.
Ref 3 The m(6)A RNA methyltransferase METTL3/METTL14 promotes leukemogenesis through the mdm2/p53 pathway in acute myeloid leukemia. J Cancer. 2022 Jan 4;13(3):1019-1030. doi: 10.7150/jca.60381. eCollection 2022.
Ref 4 MI-219-zinc combination: a new paradigm in MDM2 inhibitor-based therapy. Oncogene. 2011 Jan 6;30(1):117-26. doi: 10.1038/onc.2010.403. Epub 2010 Sep 6.